ASH 2019 | HSCT with T-cell add-back of rivogenlecleucel in acute leukemia
Annalisa Ruggeri, MD, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, discusses the comparative analysis of alpha-beta T-cell and B-cell depleted (abTCD) HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) versus abTCD haplo-HSCT with T-cell add-back of rivogenlecleucel in children with high-risk acute leukemia (AL) in remission. This phase I/II trial (NCT02065869) tested the safety and efficacy of post-transplant infusion of a titrated number of donor-derived T-cells transduced with the iC9 gene in children with high-risk AL, in order to avoid GvHD. Data confirms that the infusion of donor-derived rivogenlecleucel is safe, well tolerated and improved patients non-relapse-mortality and leukemia-free survival. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
